Revance to participate in the cantor fitzgerald 2017 global healthcare conference

Newark, calif.--(business wire)--revance therapeutics, inc. (nasdaq:rvnc), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will participate in the cantor fitzgerald 2017 global healthcare conference in new york, ny. revance management is scheduled to present on tuesday, september 26 at 1:40pm et. interested parties can access the live audio webcast for this conference from the investor relations section of the company's website at www.revance.com. the webcast replay will be available after the conclusion of the live presentation for approximately 30 days. about revance therapeutics, inc. revance, a silicon valley-based biotechnology company, is committed to the advancement of remarkable science. the company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology, orthopedics and neurology. revance's science is based upon a proprietary peptide technology, which when combined with active drug molecules, may help address current unmet needs. revance's initial focus is on developing daxibotulinumtoxina, the company's highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. the company's lead drug candidate, daxibotulinumtoxina for injection (rt002), is currently in development for the treatment of glabellar lines, cervical dystonia and plantar fasciitis with the potential to be the first long-acting neuromodulator. the company holds worldwide rights to rt002 injectable and rt001 topical and the pharmaceutical uses of its proprietary peptide technology platform. more information on revance may be found at www.revance.com. "revance therapeutics" and the revance logo are registered trademarks of revance therapeutics, inc.
RVNC Ratings Summary
RVNC Quant Ranking